76P Safety profile of adjuvant pembrolizumab (pembro) in melanoma, non-small cell lung cancer (NSCLC), and renal cell carcinoma (RCC): Pooled analysis of phase III clinical trials. (December 2022) - Luke, J.J.; Long, G.V.; Robert, C.; Carlino, M.S.; Choueiri, T.K.; Haas, N.B.; O'Brien, M.E.R.; Paz-Ares, L.; Peters, S.; Powles, T.B.; Leiby, M.A.; Lin, J.; et al.